| Статус: | Recruiting |
| Фаза: | Phase 4 |
| Начало: | 13 января 2025 г. |
| Окончание: | 31 декабря 2027 г. |
| Описание: | Study is to evaluate the efficacy of the drug Ranquilon, 1 mg tablets, at a dosage of 6 mg/day compared to the drug Afobazole, 10 mg tablets, at a dosage of 30 mg/day for the treatment of patients with anxiety disorders due to neurasthenia and adaptation disorders. |
| смотреть на ClinicalTrials.gov |
| Статус: | Recruiting |
| Фаза: | Phase 2 |
| Начало: | 14 ноября 2024 г. |
| Окончание: | 31 декабря 2026 г. |
| Описание: | Study of the efficacy and safety of using different doses of the drug Grammidin with anesthetic, metered-dose spray for local application, for the treatment of acute infectious and inflammatory diseases of the pharynx. |
| смотреть на ClinicalTrials.gov |
| Статус: | Recruiting |
| Фаза: | Phase 2 |
| Начало: | 17 октября 2024 г. |
| Окончание: | 31 декабря 2026 г. |
| Описание: | A study of the efficacy, safety, and tolerability of the drug 4-MUST at various doses compared to placebo in patients with chronic cholecystitis and biliary dyskinesia |
| смотреть на ClinicalTrials.gov |
| Статус: | Not yet recruiting |
| Фаза: | Phase 2 |
| Начало: | 1 апреля 2024 г. |
| Окончание: | 1 декабря 2025 г. |
| Описание: | Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of XC243 in patients with exacerbation of chronic cystitis. It is planned to include patients with chronic cystitis in 4 parallel groups, who will receive XC243 at a dose of 25 mg per day, 50 mg per day, 75 mg per day or placebo for 7-10 days. Efficacy will be assessed by time from first study treatment to resolution of the symptom "Pain, discomfort or burning when urination " assessed on a visual-analog scale (VAS). |
| смотреть на ClinicalTrials.gov |